Trial Profile

A Phase 1/2, Adaptive, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of Lonigutamab in Subjects With Thyroid Eye Disease (TED)

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 30 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lonigutamab (Primary)
Indications Graves ophthalmopathy
Focus Adverse reactions; Proof of concept
Acronyms TED
Sponsors ACELYRIN; Alumis; ValenzaBio

Most Recent Events

21 May 2025 According to a Alumis media release, Alumis Inc. merged with ACELYRIN, Inc. and subsequently changed its name to Alumis Inc.
17 Apr 2025 Status changed from recruiting to active, no longer recruiting.
06 Jan 2025 According to an ACELYRIN media release, company announced data from the ongoing Phase 2 trial

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com